Simultaneous downregulation of CDK inhibitors p18Ink4c and p27Kip1 is required for MEN2A-RET-mediated mitogenesis

Oncogene

Volumn 26, Issue 4, 2007, Pages 554-570

  Joshi, P P ^a   Kulkarni, M V ^a   Yu, B K ^a   Smith, K R ^a   Norton, D L ^a   Veelen, W Van ^b   Hoppener J W M ^b   Franklin, D S ^a  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

CDKI; Cell cycle; MEN; Proliferation; RET; Tumorigenesis

Indexed keywords

CYCLIN D; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2C; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PROTEIN RET;

ADRENAL TUMOR; ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION PROFILING; GENE INDUCTION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; SIPPLE SYNDROME;

ADRENAL GLAND NEOPLASMS; ANIMALS; CARCINOMA, MEDULLARY; CELL CYCLE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P18; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MODELS, BIOLOGICAL; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NIH 3T3 CELLS; ONCOGENE PROTEINS; PHEOCHROMOCYTOMA; PROTO-ONCOGENE PROTEINS C-RET; TRANSFECTION;

MUS;

EID: 33846476858     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209811     Document Type: Article

References (54)

1. Acton D, Höppener J, Lips C. (2004). Abstracts for the Ninth International Workshop on Multiple Endocrine Neoplasia (MEN2004). J Intern Med 255: 696-730.
2. Brotherton D, Dhanaraj V, Wick S, Brizuela L, Domaille P, Volyanik E et al. (1998). Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d. Nature 395: 244-250.
3. KIP1 mRNA levels in tumours of primary and secondary hyperparathyroidism. Clin Endocrinol (Oxford) 60: 389-393.
4. Celetti A, Cerrato A, Merolla F, Vitagliano D, Vecchio G, Grieco M. (2004). H4(D10S170), a gene frequently rear-ranged with RET in papillary thyroid carcinomas: functional characterization. Oncogene 23: 109-121.
5. Chiariello M, Gomez E, Gutkind J. (2000). Regulation of cyclin-dependent kinase (Cdk) 2 Thr-160 phosphorylation and activity by mitogen-activated protein kinase in late G1 phase. Biochem J 349: 869-876.
6. Kip1 for restriction point control of the fibroblast cell cycle. Science 272: 877-880.
7. Coleman M, Marshall C, Olson M. (2004). RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol 5: 355-366.
8. Conde E, Martin-Lacave I, Utrilla J, Moreno A, Gonzalez-Campora R, Galera-Davidson H. (1992). Mitotic activity of the endocrine cells in rat thyroid glands during postnatal life. Endocrinology 131: 436-440.
9. Drosten M, Hilken G, Bockmann M, Rodicker F, Mise N, Cranston A et al. (2004). Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. J Natl Cancer Inst 96: 1231-1239.
10. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel R et al. (1996). The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276: 1575-1579.
11. Kip1-deficient mice. Cell 85: 733-744.
12. KIP1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12: 2899-2911.
13. Franklin D, Godfrey V, O'Brien D, Deng C, Xiong Y. (2000). Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 20: 6147-6158.
14. INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation. Mol Biol Cell 7: 1587-1599.
15. Greulich H, Erikson R. (1998). An analysis of Mek1 signaling in cell proliferation and transformation. J Biol Chem 273: 13280-13288.
16. Iwashita T, Asai N, Murakami H, Matsuyama M, Takahasi M. (1996). Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. Oncogene 12: 481-487.
17. Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S et al. (1999). Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 18: 3919-3922.
18. Jenkins C, Xiong Y. (1995). Immunoprecipitation and immunoblotting. In: Pagano M (ed). Cell Cycle: Material and methods. Springer-Verlag: New York, pp. 250-263.
19. Juan G, Darzynkiewicz Z. (1998). Bivariate analysis of DNA content and expression of cyclin proteins. In: Robinson Zd P, Dean P, Orfao A, Rabinovitch P, Stewart C, Tanke H and Wheeless L (eds). Current Protocols in Cytometry. Wiley-Liss: New York, NY, pp 791-794.
20. Jung Y, Nakano K, Liu W, Gallick G, Ellis L. (1999). Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. Cancer Res 59: 4804-4807.
21. Kaplan D, Martin-Zanca D, Parada L. (1991). Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature 350: 158-160.
22. Kato A, Takahashi H, Takahashi Y, Matsushime H. (1997). Inactivation of the cyclin D-dependent kinase in the rat fibroblast cell line, 3Y1, induced by contact inhibition. J Biol Chem 272: 8065-8070.
23. Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15: 629-637.
24. Kawamoto Y, Takeda K, Okuno Y, Yamakawa Y, Ito Y, Taguchi R et al. (2004). Identification of RET autophosphorylation sites by mass spectrometry. J Biol Chem 279: 14213-14224.
25. Kim HS, Seo H, Yang C, Brunet JF, Kim KS. (1998). Noradrenergic-specific transcription of the dopamine beta-hydroxylase gene requires synergy of multiple cis-acting elements including at least two Phox2a-binding sites. J Neurosci 18: 8247-8260.
26. Kip1. Cell 85: 721-732.
27. Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M et al. (2005). The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci 96: 143-148.
28. Malumbres M, Barbacid M. (2001). To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1: 222-231.
29. Marsh D, Mulligan L, Eng C. (1997). RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Horm Res 47: 168-178.
30. Martin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M. (1989). Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol 9: 24-33.
31. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E et al. (1993). Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363: 458-460.
32. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707-720.
33. Pagano M, Tam S, Theodoras A, Beer-Romero P, Del Sal G, Chau V et al. (1995). Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685.
34. Perez P, Coll P, Hempstead B, Martin-Zanca D, Chao M. (1995). NGF binding to the trk tyrosine kinase receptor requires the extracellular immunoglobulin-like domains. Mol Cell Neurosci 6: 97-105.
35. Phelps DE, Hsiao KM, Li Y, Hu N, Franklin DS, Westphal E et al. (1998). Coupled transcriptional and translational control of cyclin-dependent kinase inhibitor p18INK4c expression during myogenesis. Mol Cell Biol 18: 2334-2343.
36. KIP1. Cell Growth Differ 9: 595-610.
37. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8: 9-22.
38. Russo A, Tong L, Lee J, Jeffrey P, Pavletich N. (1998). Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395: 237-243.
39. Santoro M, Carlomagno F, Romano A, Bottaro D, Dathan N, Grieco M et al. (1995). Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267: 381-383.
40. Santoro M, Wong W, Aroca P, Santos E, Matoskova B, Grieco M et al. (1994). An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway. Mol Cell Biol 14: 663-675.
41. Schuringa J, Wojtachnio K, Hagens W, Vellenga E, Buys C, Hofstra R et al. (2001). MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene 20: 5350-5358.
42. Sherr C, Roberts J. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512.
43. Sozzi G, Pierotti M, Miozzo M, Donghi R, Radice P, De Benedetti V et al. (1991). Refined localization to contiguous regions on chromosome 10q of the two genes (H4 and RET) that form the oncogenic sequence PTC. Oncogene 6: 339-342.
44. Takahashi M, Asai N, Iwashita T, Isomura T, Miyazaki K, Matsuyama M. (1993). Characterization of the ret protooncogene products expressed in mouse L cells. Oncogene 8: 2925-2929.
45. Takahashi M, Buma Y, Taniguchi M. (1991). Identification of the ret proto-oncogene products in neuroblastoma and leukemia cells. Oncogene 6: 297-301.
46. Tischler AS, Ruzicka LA, Donahue SR, DeLellis RA. (1989). Chromaffin cell proliferation in the adult rat adrenal medulla. Int J Dev Neurosci 7: 439-448.
47. Tong Q, Li Y, Smanik P, Fithian L, Xing S, Mazzaferri E et al. (1995). Characterization of the promoter region and oligomerization domain of H4 (D10S170), a gene frequently rearranged with the ret proto-oncogene. Oncogene 10: 1781-1787.
48. Trupp M, Scott R, Whittemore S, Ibanez C. (1999). Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. J Biol Chem 274: 20885-20894.
49. van Weering D, Bos J. (1998). Signal transduction by the receptor tyrosine kinase Ret. Recent Results Cancer Res 154: 271-281.
50. van Weering D, Medema J, van Puijenbroek A, Burgering B, Baas P, Bos J. (1995). Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells. Oncogene 11: 2207-2214.
51. Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. Cancer Res 64: 3823-3829.
52. Watanabe T, Ichihara M, Hashimoto M, Shimono K, Shimoyama Y, Nagasaka T et al. (2002). Characterization of gene expression induced by RET with MEN2A or MEN2B mutation. Am J Pathol 161: 249-256.
53. Weber J, Hu W, Jefcoat Jr S, Raben D, Baldassare J. (1997). Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27. J Biol Chem 272: 32966-32971.
54. Worby C, Vega Q, Zhao Y, Chao H, Seasholtz A, Dixon J. (1996). Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase. J Biol Chem 271: 23619-23622.